Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
Guidance Documents/Guidance-Document/Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment

Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment

Detailed guidance document from FDA and regulatory agencies.

Document Details

Guidance Document

February 7, 2019

January 17, 2020

Center for Drug Evaluation and Research

f53ca142-5456-4eec-9cc0-358980e372cd

Related Documents

Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry

Guidance DocumentSeptember 6, 2018Center for Drug Evaluation and Research
View Details →

Nonallergic Rhinitis: Developing Drug Products for Treatment

Guidance DocumentSeptember 6, 2018Center for Drug Evaluation and Research
View Details →

Migraine: Developing Drugs for Acute Treatment

Guidance DocumentFebruary 16, 2018Center for Drug Evaluation and Research
View Details →

Quick Actions

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.

KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.